The clinical trials for Leqembi and Kisunla demonstrated that clearing out beta-amyloid plaques is linked with a small slowing in cognitive decline over 18 months. Since it doesn’t reverse or halt the disease’s progress, scientists think that tau proteins and other factors like inflammation might also play a role in Alzheimer’s.